arrow_back Back to App

Increased Access to Biosimilar Drugs in Medicare Program

This act establishes a pilot program to increase the availability of more affordable biosimilar drugs for individuals covered by Medicare. Through this program, healthcare providers can receive additional payments for using these drugs, which aims to encourage their wider adoption and potentially lower treatment costs for patients.
Key points
A 5-year pilot program aims to encourage the use of more affordable biosimilar drugs in Medicare.
Healthcare providers may receive extra payments for choosing biosimilar drugs if they are cheaper than original products.
Participation in the program is voluntary for providers, and Medicare patients could potentially pay less for biosimilar drugs.
Data on patients will be collected to assess the program's impact on various social groups.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_1427
Sponsor: Sen. Cornyn, John [R-TX]
Process start date: 2021-04-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Increasing Access to Biosimilars Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_1427.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • A 5-year pilot program aims to encourage the use of more affordable biosimilar drugs in Medicare.
  • Healthcare providers may receive extra payments for choosing biosimilar drugs if they are cheaper than original products.
  • Participation in the program is voluntary for providers, and Medicare patients could potentially pay less for biosimilar drugs.
  • Data on patients will be collected to assess the program's impact on various social groups.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Cornyn, John [R-TX].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health